Healthcare provider profile · identity verified

Johnny J Abidin, MD

Internal Medicine · LANCASTER, OH · NPI 1902885403

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	258	90
Lisinopril	Lisinopril	242	79
Omeprazole	Omeprazole	222	89
Pravastatin Sodium	Pravastatin Sodium	220	83
Levothyroxine Sodium	Levothyroxine Sodium	197	74
Amlodipine Besylate	Amlodipine Besylate	190	74
Rosuvastatin Calcium	Rosuvastatin Calcium	159	55
Metformin Hcl	Metformin Hcl	151	44
Gabapentin	Gabapentin	125	33
Eliquis	Apixaban	110	26
Losartan Potassium	Losartan Potassium	104	39
Metoprolol Tartrate	Metoprolol Tartrate	104	39
Furosemide	Furosemide	95	38
Potassium Chloride	Potassium Chloride	92	40
Hydrochlorothiazide	Hydrochlorothiazide	85	29
Simvastatin	Simvastatin	85	30
Sertraline Hcl	Sertraline Hcl	80	31
Tamsulosin Hcl	Tamsulosin Hcl	79	29
Albuterol Sulfate Hfa	Albuterol Sulfate	73	30
Alprazolam	Alprazolam	72	21
Ezetimibe	Ezetimibe	68	23
Pioglitazone Hcl	Pioglitazone Hcl	68	22
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	63	18
Jardiance	Empagliflozin	60	19
Citalopram Hbr	Citalopram Hydrobromide	58	16
Escitalopram Oxalate	Escitalopram Oxalate	56	20
Metoprolol Succinate	Metoprolol Succinate	56	25
Clopidogrel	Clopidogrel Bisulfate	54	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	54	22
Tizanidine Hcl	Tizanidine Hcl	54	24
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	53	18
Carvedilol	Carvedilol	51	16
Memantine Hcl	Memantine Hcl	50	20
Pantoprazole Sodium	Pantoprazole Sodium	50	24
Allopurinol	Allopurinol	49	14
Ozempic	Semaglutide	48	11
Glimepiride	Glimepiride	46	16
Isosorbide Mononitrate Er	Isosorbide Mononitrate	46	13
Nifedipine Er	Nifedipine	46	19
Tramadol Hcl	Tramadol Hcl	45	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	43	suppressed
Ibandronate Sodium	Ibandronate Sodium	43	16
Alendronate Sodium	Alendronate Sodium	42	15
Glipizide	Glipizide	42	suppressed
Fenofibrate	Fenofibrate	41	19
Trazodone Hcl	Trazodone Hcl	39	16
Hydralazine Hcl	Hydralazine Hcl	38	11
Mirtazapine	Mirtazapine	38	11
Xarelto	Rivaroxaban	34	12
Clonazepam	Clonazepam	33	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	33	suppressed
Fluticasone Propionate	Fluticasone Propionate	33	suppressed
Atenolol	Atenolol	32	11
Klor-Con M20	Potassium Chloride	32	11
Primidone	Primidone	32	suppressed
Donepezil Hcl	Donepezil Hcl	30	13
Gemfibrozil	Gemfibrozil	30	11
Montelukast Sodium	Montelukast Sodium	30	11
Finasteride	Finasteride	29	14
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	28	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	27	suppressed
Liothyronine Sodium	Liothyronine Sodium	25	suppressed
Januvia	Sitagliptin Phosphate	24	suppressed
Meclizine Hcl	Meclizine Hcl	24	15
Oxaprozin	Oxaprozin	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Ropinirole Hcl	Ropinirole Hcl	24	suppressed
Valsartan	Valsartan	24	suppressed
Warfarin Sodium	Warfarin Sodium	23	suppressed
Spironolactone	Spironolactone	22	11
Esomeprazole Magnesium	Esomeprazole Magnesium	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Methylprednisolone	Methylprednisolone	21	18
Benazepril Hcl	Benazepril Hcl	20	suppressed
Bupropion Xl	Bupropion Hcl	20	suppressed
Diazepam	Diazepam	20	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Levemir Flexpen	Insulin Detemir	20	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	20	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	20	suppressed
Duloxetine Hcl	Duloxetine Hcl	19	suppressed
Synthroid	Levothyroxine Sodium	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Levofloxacin	Levofloxacin	18	17
Lorazepam	Lorazepam	18	suppressed
Farxiga	Dapagliflozin Propanediol	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Prednisone	Prednisone	16	suppressed
Ramipril	Ramipril	16	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Metformin Hcl Er	Metformin Hcl	15	suppressed
Torsemide	Torsemide	15	suppressed
Verapamil Er	Verapamil Hcl	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	14	suppressed
Levetiracetam	Levetiracetam	14	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	12
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Lexapro	Escitalopram Oxalate	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Topiramate	Topiramate	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	12
Celecoxib	Celecoxib	12	suppressed
Tresiba Flextouch U-100	Insulin Degludec	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error